Tugnait M - Search Results

1

In vitro ADME phenotyping in drug discovery: current challenges and future solutions.

Williams JA, Bauman J, Cai H, Conlon K, Hansel S, Hurst S, Sadagopan N, Tugnait M, Zhang L, Sahi J. Williams JA, et al. Among authors: tugnait m. Curr Opin Drug Discov Devel. 2005 Jan;8(1):78-88. Curr Opin Drug Discov Devel. 2005. PMID: 15679175 Review.

2

Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes.

Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst SI, Menning LC, Milad M, Court MH, Williams JA. Bauman JN, et al. Among authors: tugnait m. Drug Metab Dispos. 2005 Sep;33(9):1349-54. doi: 10.1124/dmd.105.005108. Epub 2005 Jun 24. Drug Metab Dispos. 2005. PMID: 15980101

3

Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.

Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye Y, de Morais SM, Black C, Tugnait M, Keller LH. Sahi J, et al. Among authors: tugnait m. Chem Biol Interact. 2006 Feb 1;159(2):156-68. doi: 10.1016/j.cbi.2005.11.001. Epub 2005 Dec 13. Chem Biol Interact. 2006. PMID: 16356485 Clinical Trial.

4

Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation.

Ramanathan R, McKenzie DL, Tugnait M, Siebenaler K. Ramanathan R, et al. Among authors: tugnait m. J Pharm Biomed Anal. 2002 Jun 1;28(5):945-51. doi: 10.1016/s0731-7085(01)00707-5. J Pharm Biomed Anal. 2002. PMID: 12039637

5

Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.

Kalgutkar AS, Tugnait M, Zhu T, Kimoto E, Miao Z, Mascitti V, Yang X, Tan B, Walsky RL, Chupka J, Feng B, Robinson RP. Kalgutkar AS, et al. Among authors: tugnait m. Drug Metab Dispos. 2011 Sep;39(9):1609-19. doi: 10.1124/dmd.111.040675. Epub 2011 Jun 20. Drug Metab Dispos. 2011. PMID: 21690265 Clinical Trial.

6

Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.

Maurer TS, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari CM, She L, Leininger MT, Zhu T, Tugnait M, Yang X, Kimoto E, Mascitti V, Robinson RP. Maurer TS, et al. Among authors: tugnait m. AAPS J. 2011 Dec;13(4):576-84. doi: 10.1208/s12248-011-9297-2. Epub 2011 Aug 26. AAPS J. 2011. PMID: 21870203 Free PMC article.

7

Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.

Miao Z, Nucci G, Amin N, Sharma R, Mascitti V, Tugnait M, Vaz AD, Callegari E, Kalgutkar AS. Miao Z, et al. Among authors: tugnait m. Drug Metab Dispos. 2013 Feb;41(2):445-56. doi: 10.1124/dmd.112.049551. Epub 2012 Nov 20. Drug Metab Dispos. 2013. PMID: 23169609 Clinical Trial.

8

The metabolism of 4-trifluoromethoxyaniline and [13C]-4-trifluoromethoxyacetanilide in the rat: detection and identification of metabolites excreted in the urine by NMR and HPLC-NMR.

Tugnait M, Lenz EM, Phillips P, Hofmann M, Spraul M, Lindon JC, Nicholson JK, Wilson ID. Tugnait M, et al. J Pharm Biomed Anal. 2002 Jun 1;28(5):875-85. doi: 10.1016/s0731-7085(01)00699-9. J Pharm Biomed Anal. 2002. PMID: 12039629

9

Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.

Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, Leininger MT, Lowe A, Maguire RJ, Masterson VM, Miao Z, Mukaiyama E, Patel JD, Pettersen JC, Préville C, Samas B, She L, Sobol Z, Steppan CM, Stevens BD, Thuma BA, Tugnait M, Zeng D, Zhu T. Mascitti V, et al. Among authors: tugnait m. J Med Chem. 2011 Apr 28;54(8):2952-60. doi: 10.1021/jm200049r. Epub 2011 Mar 30. J Med Chem. 2011. PMID: 21449606

10

The metabolism of 2-trifluormethylaniline and its acetanilide in the rat by 19F NMR monitored enzyme hydrolysis and 1H/19F HPLC-NMR spectroscopy.

Tugnait M, Lenz EM, Hofmann M, Spraul M, Wilson ID, Lindon JC, Nicholson JK. Tugnait M, et al. J Pharm Biomed Anal. 2003 Jan 1;30(5):1561-74. doi: 10.1016/s0731-7085(02)00546-0. J Pharm Biomed Anal. 2003. PMID: 12467928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page